Bristol-Myers Squibb Co vs United States Oil ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.68 (market cap $129.94B), while United States Oil ETF trades at $127.2. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while United States Oil ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| BMY | USO | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $152.96 |
52-Week Low | $42.60 | $66.17 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
USO is trading at $126.49, up 0.45% with bullish technical momentum as moving averages signal strength. The stock faces mixed sentiment amid ongoing Middle East supply disruptions and OPEC demand forecast revisions. Recent headlines highlight volatility from Hormuz tensions and shifting oil market dynamics.
Outlook remains volatile with supply risks supporting prices but demand concerns creating headwinds. Key resistance at $128-$132 and support at $123-$119 will dictate near-term direction. Geopolitical developments and inventory data remain critical catalysts for oil-linked equities.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →